Navigation Links
Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
Date:10/25/2010

, France, and at the European Society for Gene and Cell Therapy Annual Conference (22-25 October) in Milan, Italy.

In the new study, mice received intra-venous injections with equal doses of 1011 gc per animal AAV-shApoB or AAV-miApoB and were examined for 18 weeks. Expression of the shApoB and miApoB resulted in 90% ApoB protein knock-down, associated with 80% cholesterol decrease in murine plasma for the first 6 weeks. However, after 8 weeks the effect of the shApoB started to wear off, while miApoB remained effective in ApoB and cholesterol reduction for up to 18 weeks. Ongoing research aims to determine the mechanism for the differences seen between long-term AAV-shApoB and AAV-miApoB efficacy in murine livers. We believe that the long-term stability of the miApoB is due to its lower toxicity and off-target properties compared to shApoB because expression of miApoB is specifically limited to hepatocytes.

ApoB100 is the structural protein of Low Density Lipoprotein (LDL) particles that carry cholesterol. Silencing the activity of ApoB100 with miRNA or shRNA lowers plasma LDL-cholesterol by 60-80% and has the potential to be used to treat hypercholesterolemia and associated cardiovascular disease.

About Amsterdam Molecular Therapeutics

AMT is a leader in the development of human gene based therapies. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This proprietary platform can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPLD, Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria, and Parkinson's Disease at different stages of research or development. AMT was founded in 1998 and is based in Amsterdam.

'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
3. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
8. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
9. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
10. New Data Suggest Veracytes Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
11. Launch of Two New Platforms for Microplate Analysis Expands Reader Portfolio and Ensures Molecular Devices Readers Meet all Combinations of Customer Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... , May 20, 2015  Select Medical ... the Federal Trade Commission granted early termination of ... Improvements Act of 1976, as amended, applicable to ... Acquisition Corporation, a joint venture that Select has ... As previously announced, MJ Acquisition Corporation ...
(Date:5/20/2015)... 20, 2015 Agricultural firm H.J. Baker ... its acquisition of Tiger-Sul. Since the purchase of ... Canada) in May 2005, H.J. Baker has leveraged the ... into a comprehensive portfolio of product offerings and solutions ... Baker and the innovation of Tiger-Sul, transforming the company ...
(Date:5/20/2015)... 2015  Cypher Genomics, Inc., a leading genome ... Corporation to apply Cypher,s Coral TM technology ... patient response to innovative medicines. The information generated ... patient access to the right medicine at the ... development and potentially inform new companion diagnostics.  ...
(Date:5/20/2015)... , 20. Mai 2015 /PRNewswire/ ... klinische Logistik (Clinical Logistics Organization/CLO) hat ... 2014, das am 31. Dezember 2014 ... hat die Marktentwicklung übertroffen und sein ... http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
Breaking Biology Technology:Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2
... Breast Cancer, PARSIPPANY, N.J., Sept. 22 Who ... your teens and your 50s could increase your risk,of ... out about the,link between excess weight and breast cancer, ... and improve their health, but to also help,deal with ...
... A study in northern China indicates that genetically modified cotton, ... populations among those crops, but also reduces pests among other ... findings could offer promising new ideas for controlling pests and ... will be published by the journal Science on ...
... billions of cells that continually transmit signals to each ... learn, remember, and so much more − works only ... other words, when there is a good ,synapse,. An ... production along with the synapse. VIB researchers connected to ...
Cached Biology Technology:alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both 2alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both 3GM crops protect neighbors from pests 2Revealing the regulating mechanism behind signal transduction in the brain 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/6/2015)... LifeBEAM, a developer of bio-sensing technology, and ... that they will expand their partnership in bio-sensing sports ... helmet and the first joint project between the two ... order to give cyclists more style choices and meet ... Lazer announced their plan to release a new generation ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... the Earth,s greatest extinction event that took place 250 million ... marine species and a majority of those on land. Now, ... annihilation: an influx of mercury into the eco-system. "No ... potential culprit. This was a time of the greatest volcanic ...
... storage more cost-effective, a group of researchers from National Tsing ... in Germany have created a DNA-based memory device that is ... it possible to encode information. The device, described in a ... consists of a thin film of salmon DNA that has ...
... FL Sathyanaryanan Puthanveettil, an assistant professor on the ... awarded a pair of notable grants to study a ... will receive $225,000 over three years from the prestigious ... of a motor protein called kinesin. In this study, ...
Cached Biology News:Earth's massive extinction: The story gets worse 2Scripps Research Scientist wins pair of grants to study critical component of memory 2
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
... Smart Minis 300V power supply (Cat. No. ... voltage, sufficient for SDS-PAGE, and native PAGE ... pairs of terminator pairs can be used ... for individuals to have his/her own power ...
... NightOWL is a dedicated imaging system for ... light due to pixel size. Equipped with ... level light in animals or plants in ... circadian rhythm or Western blots. NightOWL is ...
... NovaTaq DNA Polymerase is a premium ... polymerase. This thermostable enzyme is suitable for ... ensure the highest purity and reproducible performance, ... variety of quality control assays. NovaTaq DNA ...
Biology Products: